The rediscovery of platinum-based cancer therapy
S Rottenberg, C Disler, P Perego - Nature Reviews Cancer, 2021 - nature.com
Platinum (Pt) compounds entered the clinic as anticancer agents when cisplatin was
approved in 1978. More than 40 years later, even in the era of precision medicine and …
approved in 1978. More than 40 years later, even in the era of precision medicine and …
[HTML][HTML] Targeting NaPi2b in ovarian cancer
S Banerjee, R Drapkin, DL Richardson… - Cancer Treatment …, 2023 - Elsevier
Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for
which the standard of care remains heavily focused on platinum-based chemotherapy …
which the standard of care remains heavily focused on platinum-based chemotherapy …
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label …
Background The benefits of secondary cytoreduction for platinum-sensitive relapsed ovarian
cancer are still widely debated. We aimed to assess the efficacy of secondary cytoreduction …
cancer are still widely debated. We aimed to assess the efficacy of secondary cytoreduction …
NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions
H Luo, Y Zhou, J Zhang, Y Zhang, S Long… - Frontiers in …, 2023 - frontiersin.org
Exosomes are membranous vesicles actively secreted by almost all cells and they deliver
certain intracellular molecules, including nucleic acids, proteins, and lipids, to target cells …
certain intracellular molecules, including nucleic acids, proteins, and lipids, to target cells …
Metabolomics profiling and chemoresistance mechanisms in ovarian cancer cell lines: Implications for targeting glutathione pathway
P Alarcon-Zapata, AJ Perez, K Toledo-Oñate… - Life Sciences, 2023 - Elsevier
Ovarian cancer presents a significant challenge due to its high rate of chemoresistance,
which complicates the effectiveness of drug-response therapy. This study provides a …
which complicates the effectiveness of drug-response therapy. This study provides a …
Lidocaine inhibits the metastatic potential of ovarian cancer by blocking NaV1.5‐mediated EMT and FAK/Paxillin signaling pathway
C Liu, M Yu, Y Li, H Wang, C Xu, X Zhang… - Cancer …, 2021 - Wiley Online Library
Lidocaine, one of the most commonly used local anesthetics during surgery, has been
reported to suppress cancer cell growth via blocking voltage‐gated sodium channels …
reported to suppress cancer cell growth via blocking voltage‐gated sodium channels …
SLC7A1 overexpression is involved in energy metabolism reprogramming to induce tumor progression in epithelial ovarian cancer and is associated with immune …
S You, X Zhu, Y Yang, XZ Du, K Song… - Journal of …, 2022 - Wiley Online Library
Cationic amino acid transporters (SLC7A1/CAT1) are highly expressed in human ovarian
cancer (OC) tissues. However, the specific biological functions and mechanisms involved …
cancer (OC) tissues. However, the specific biological functions and mechanisms involved …
A risk score model incorporating three m6A RNA methylation regulators and a related network of miRNAs-m6A regulators-m6A target genes to predict the prognosis of …
Q Li, CC Ren, YN Chen, L Yang, F Zhang… - Frontiers in cell and …, 2021 - frontiersin.org
Ovarian cancer (OC) is the leading cause of cancer-related death among all gynecological
tumors. N6-methyladenosine (m6A)-related regulators play essential roles in various tumors …
tumors. N6-methyladenosine (m6A)-related regulators play essential roles in various tumors …
Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer
X Liu, Z Yin, Y Wu, Q Zhan, H Huang, J Fan - Bioengineered, 2022 - Taylor & Francis
Circular RNA (circRNA) is considered to be an important regulator that mediates cancer
chemoresistance. But whether circ-LPAR3 is involved in ovarian cancer (OC) cisplatin …
chemoresistance. But whether circ-LPAR3 is involved in ovarian cancer (OC) cisplatin …
Parasites revive hope for cancer therapy
MM Eissa, AE Salem, N El Skhawy - European Journal of Medical …, 2024 - Springer
Parasites have attained a life-long stigma of being detrimental organisms with deleterious
outcomes. Yet, recently, a creditable twist was verified that can dramatically change our …
outcomes. Yet, recently, a creditable twist was verified that can dramatically change our …